AGEAS

HEALTH CHECK

16/05/24 -"As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from the fact that delivery hinges on buying the next ..."

PDF page sample
Pages
49
Language
English
Published on
16/05/24
Download
You may also be interested by these reports :
12/12/24
• Underlying earnings per share CAGR of 9-11% for 2025-2027. • Underlying RoE target of 13-16% for 2025-2027. • Cumulative dividend payments of over ...
11/12/24
• Net income growth by 30% to more than €2.5bn by 2027. • DPS of €2.70 for FY2024 compared to €2.35 for FY2023. • DPS prospect of further rise by ...
10/12/24
• Earnings per share CAGR of 7-9% based on core earnings for 2024-2027. • Return on equity of at least 17% based on core earnings for 2024-2027. • ...
10/12/24
Accounting amounts to an attempt to instil a shared fixed point in financial matters. For insurers, one particularly key financial fixed point – ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO